Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093007 | 1.00 | PARP1 (0.33) | PARP1HTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL6090997 | 0.92 | BRD4 (0.37) | PARP1HTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL6089785 | 0.92 | BRD4 (0.37) | PARP1HTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL6089125 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1NPSR1TNKS2 | |
| SCHEMBL6089444 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1NPSR1TNKS2 | |
| SCHEMBL6091289 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1NPSR1TNKS2 | |
| SCHEMBL6092971 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1NPSR1TNKS2 | |
| Hydrochloric Acid SCHEMBL6091722 | 0.86 | KDM4E (0.41) | HTR2CHTR2BKDM4EALDH1A1NPSR1 | |
| SCHEMBL6090392 | 0.84 | TNKS2 (0.39) | PARP1HTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL6089696 | 0.84 | TNKS2 (0.39) | PARP1HTR2CHTR2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1582520-A1 | NOVEL PARP INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | PARP1, PARP2, PARP11 | PARP1 1/4885HTR2C 3206/4885HTR2B 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.